Toggle light / dark theme

Brain Organoids as Model Systems for Genetic Neurodevelopmental Disorders

Neurodevelopmental disorders (NDDs) are a group of disorders in which the development of the central nervous system (CNS) is disturbed, resulting in different neurological and neuropsychiatric features, such as impaired motor function, learning, language or non-verbal communication. Frequent comorbidities include epilepsy and movement disorders. Advances in DNA sequencing technologies revealed identifiable genetic causes in an increasingly large proportion of NDDs, highlighting the need of experimental approaches to investigate the defective genes and the molecular pathways implicated in abnormal brain development. However, targeted approaches to investigate specific molecular defects and their implications in human brain dysfunction are prevented by limited access to patient-derived brain tissues. In this context, advances of both stem cell technologies and genome editing strategies during the last decade led to the generation of three-dimensional (3D) in vitro-models of cerebral organoids, holding the potential to recapitulate precise stages of human brain development with the aim of personalized diagnostic and therapeutic approaches. Recent progresses allowed to generate 3D-structures of both neuronal and non-neuronal cell types and develop either whole-brain or region-specific cerebral organoids in order to investigate in vitro key brain developmental processes, such as neuronal cell morphogenesis, migration and connectivity. In this review, we summarized emerging methodological approaches in the field of brain organoid technologies and their application to dissect disease mechanisms underlying an array of pediatric brain developmental disorders, with a particular focus on autism spectrum disorders (ASDs) and epileptic encephalopathies.

Neurodevelopmental disorders (NDDs) encompass a range of frequently co-existing conditions that include intellectual disability (ID), developmental delay (DD), and autism spectrum disorders (ASDs) (Heyne et al., 2018; Salpietro et al., 2019). ASDs represent a complex set of behaviorally defined phenotypes, characterized by impairments in social interaction, communication and restricted or stereotyped behaviors (Chen et al., 2018). Epilepsy and NDDs frequently occur together, and when refractory seizures are accompanied by cognitive slowing or regression, patients are considered to have an epileptic encephalopathy (EE) (Scheffer et al., 2017). Both ID and ASDs are clinically and etiologically heterogeneous and a unifying pathophysiology has not yet been identified for either the disorder as a whole or its core behavioral components (Myers et al., 2020). Family and twin studies suggest high (0.65–0.91) heritability (Chen et al.

Scientists Propose New Method To Detect Consciousness in Infants

Academics are proposing a new and improved way to help researchers discover when consciousness emerges in human infancy.

When over the course of development do humans become conscious? When the seventeenth-century French philosopher René Descartes was asked about infant consciousness by his critics, he eventually suggested that infants might have thoughts, albeit ones that are simpler than those of adults. Hundreds of years later, the issue of when human beings become conscious is a question which remains a challenge for psychologists and philosophers alike.

But now, in response to a recent article in Trends in Cognitive Sciences, two academics from the University of Birmingham have suggested an improved way to help scientists and researchers identify when babies become conscious.

The potential of ultrasound and antibodies for Alzheimer’s disease therapy

Professor Jürgen Götz and Dr Pranesh Padmanabhan from the Queensland Brain Institute comment on the successful human trial by the WVU Rockefeller Neuroscience Institute which found a five-fold reduction of amyloid-β in Alzheimer’s patients.

The latest trial results underscore the safety of using…


The potentially powerful combination of ultrasound and antibodies for the treatment of Alzheimer’s disease is the focus of a News & Views article by UQ’s Queensland Brain Institute (QBI) researchers.

QBI Professor Jürgen Götz and his team aim to develop low-intensity ultrasound into a treatment modality for Alzheimer’s disease.

Ultrasound can be used with microbubbles to achieve blood-brain barrier opening for drug delivery, or it can be used without bubbles to modulate brain function.

World first supercomputer capable of brain-scale simulation being built at Western Sydney University

😗😁😘 year 2023.


The world’s first supercomputer capable of simulating networks at the scale of the human brain has been announced by researchers at the International Centre for Neuromorphic Systems (ICNS) at Western Sydney University.

DeepSouth uses a neuromorphic system which mimics biological processes, using hardware to efficiently emulate large networks of spiking neurons at 228 trillion synaptic operations per second — rivalling the estimated rate of operations in the human brain.

ICNS Director, Professor André van Schaik says DeepSouth stands apart from other supercomputers as it is purpose-built to operate like networks of neurons, requiring less power and enabling greater efficiencies. This contrasts with supercomputers optimised for more traditional computing loads, which are power hungry.

Mental health chatbots effective in treating depression symptoms: NTU study

Mental health chatbots can help treat symptoms of depression, according to findings from an NTU research team. These apps can interact with people to show empathy and encouragement, to improve moods. CNA spoke to Dr Laura Martinengo, Research Fellow at Lee Kong Chian School of Medicine at NTU.

Follow us:
CNA: https://cna.asia.
CNA Lifestyle: http://www.cnalifestyle.com.
Facebook: / channelnewsasia.
Instagram: / channelnewsasia.
Twitter: / channelnewsasia.
TikTok: / channelnewsasia.

Team develops Fluid Biomarker for Early Detection of Amyotrophic Lateral Sclerosis, ALS and Frontotemporal Dementia

Two progressively degenerative diseases, amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig’s disease) and frontotemporal dementia (FTD, recently in the news with the diagnoses of actor Bruce Willis and talk show host Wendy Williams), are linked by more than the fact that they both damage nerve cells critical to normal functioning—the former affecting nerves in the brain and spinal cord leading to loss of movement, the latter eroding the brain regions controlling personality, behavior and language.

Research studies have repeatedly shown that in patients with ALS or FTD, the function of TAR DNA-binding protein 43, more commonly called TDP-43, becomes corrupted. When this happens, pieces of the genetic material called ribonucleic acid (RNA) can no longer be properly spliced together to form the coded instructions needed to direct the manufacture of other proteins required for healthy nerve growth and function.

The RNA strands become riddled with erroneous code sequences called “cryptic exons” that instead affect proteins believed to be associated with increased risk for ALS and FTD development.

Memories are made by breaking DNA — and fixing it

When a long-term memory forms, some brain cells experience a rush of electrical activity so strong that it snaps their DNA. Then, an inflammatory response kicks in, repairing this damage and helping to cement the memory, a study in mice shows. The findings, published on 27 March in Nature1, are “extremely exciting”, says Li-Huei Tsai, a neurobiologist at the Massachusetts Institute of Technology in Cambridge who was not involved in the work. They contribute to the picture that forming memories is a “risky business”, she says. Normally, breaks in both strands of the double helix DNA molecule are associated with diseases including cancer. But in this case, the DNA damage-and-repair cycle offers one explanation for how memories might form and last.

It also suggests a tantalizing possibility: this cycle might be faulty in people with neurodegenerative diseases such as Alzheimer’s, causing a build-up of errors in a neuron’s DNA, says study co-author Jelena Radulovic, a neuroscientist at the Albert Einstein College of Medicine in New York City.